e-learning
resources
London 2016
Sunday, 04.09.2016
Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Samy Suissa (Montreal, Canada), Samy Suissa, Sophie Dell’Aniello, Pierre Ernst
Source:
International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Session:
Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Session type:
Thematic Poster
Number:
993
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Samy Suissa (Montreal, Canada), Samy Suissa, Sophie Dell’Aniello, Pierre Ernst. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study. Eur Respir J 2016; 48: Suppl. 60, 993
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Long-term inhaled corticosteroid use in COPD and the risk of fracture in men and women
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016
Year: 2017
Safety of tiotropium in patients with cardiac events in the TIOSPIR™ trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Statin use and risk of exacerbations in individuals with COPD: The Copenhagen general population study
Source: International Congress 2014 – New insights into the epidemiology of COPD
Year: 2014
Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes
Source: International Congress 2014 – Markers
Year: 2014
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Predictors of long-term mortality after hospitalization for COPD; A Scandinavian multicentre study
Source: International Congress 2014 – Longitudinal studies of respiratory disease
Year: 2014
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Use of beta-blockers in COPD patients with heart-disease. BBEPOC study
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD
Source: Eur Respir J 2010; 36: 494-502
Year: 2010
Safety of tiotropium in patients with cardiac events in the UPLIFT® trial
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept